A5108063776- Particle physics theoretical and experimental studies
- Quantum Chromodynamics and Particle Interactions
- High-Energy Particle Collisions Research
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Neutrino Physics Research
- Dark Matter and Cosmic Phenomena
- Gastrointestinal Tumor Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- RNA modifications and cancer
- Genetic factors in colorectal cancer
- Particle Detector Development and Performance
- Metastasis and carcinoma case studies
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Helicobacter pylori-related gastroenterology studies
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Cancer-related gene regulation
- Cancer-related Molecular Pathways
- Particle Accelerators and Free-Electron Lasers
- Cosmology and Gravitation Theories
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
Yonsei University
2015-2024
Gangnam Severance Hospital
2015-2024
Yonsei University Health System
2022-2023
Center for Systems Biology
2023
Sungkyunkwan University
2013-2022
Université Paris Cité
1996-2022
Centre National de la Recherche Scientifique
1997-2022
Université Paris-Sud
1998-2022
Severance Hospital
2007-2021
A. Alikhanyan National Laboratory
2012-2019
Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) trametinib (MEK combination therapy in BRAF V600E-mutated anaplastic thyroid cancer, a rare, aggressive, highly lethal malignancy with poor patient outcomes no systemic therapies clinical benefit. Methods In this phase II, open-label trial, patients predefined malignancies received 150 mg twice daily 2 once until unacceptable toxicity, disease progression, or death. The primary end point was investigator-assessed...
The cross section for ee+ e- → π+ π- J/ψ between 3.8 and 5.5 GeV is measured with a 967 fb(-1) data sample collected by the Belle detector at or near Υ(nS) (n = 1,2,…,5) resonances. Y(4260) state observed, its resonance parameters are determined. In addition, an excess of production around 4 observed. This feature can be described Breit-Wigner parametrization properties that consistent Y(4008) was previously reported Belle. study decays, structure observed in M(π(±)J/ψ) mass spectrum 5.2σ...
We report the observation of two narrow structures in mass spectra pi+-Y(nS) (n=1,2,3) and pi+-hb(mP)(m$ (m=1,2) pairs that are produced association with a single charged pion Y(5S) decays. The measured masses widths averaged over five final states M_1=(10607.2+-2.0) MeV/c2, Gamma_1=(18.4+-2.4) MeV M_2=(10652.2+-1.5) Gamma_2=(11.5+-2.2) MeV. results obtained 121.4 1/fb data sample collected Belle detector vicinity resonance at KEKB asymmetric-energy e+e- collider.
Abstract Purpose: The Cancer Genome Atlas (TCGA) project recently uncovered four molecular subtypes of gastric cancer: Epstein–Barr virus (EBV), microsatellite instability (MSI), genomically stable (GS), and chromosomal (CIN). However, their clinical significances are currently unknown. We aimed to investigate the relationship between prognosis patients with cancer. Experimental Design: Gene expression data from a TCGA cohort (n = 262) were used develop subtype prediction model, association...
Gastric cancer is a heterogeneous cancer, making treatment responses difficult to predict. Here we show that identify two distinct molecular subtypes, mesenchymal phenotype (MP) and epithelial (EP), by analyzing genomic proteomic data. Molecularly, MP subtype tumors high integrity characterized low mutation rates microsatellite stability, whereas EP integrity. Clinically, the associated with markedly poor survival resistance standard chemotherapy, better sensitivity chemotherapy. Integrative...
Despite continual efforts to develop a prognostic model of gastric cancer by using clinical and pathologic parameters, test that can discriminate patients with good outcomes from those poor after surgery has not been established. We aim practical biomarker-based risk score predict relapse surgical treatment.Microarray technologies were used generate analyze gene expression profiling data 65 identify biomarker genes associated relapse. The association patterns identified overall survival was...
Purpose Gastric cancer cell lines, particularly those with low levels of ataxia telangiectasia mutated (ATM), a key activator DNA damage response, are sensitive to the poly (ADP-ribose) polymerase inhibitor olaparib. We compared efficacy olaparib plus paclitaxel (olaparib/paclitaxel) alone in patients recurrent or metastatic gastric and assessed whether ATM expression is predictive improved clinical outcome for olaparib/paclitaxel. Patients Methods In this phase II, double-blind study (Study...
With the full data sample of $772 \times 10^6$ $B{\bar B}$ pairs recorded by Belle detector at KEKB electron-positron collider, decay $\bar{B} \rightarrow D^* \tau^- \bar{\nu}_\tau$ is studied with hadronic $\tau$ decays $\tau^- \pi^- \nu_\tau$ and \rho^- \nu_\tau$. The polarization $P_\tau(D^*)$ in two-body measured, as well ratio branching fractions $R(D^{*}) = \mathcal{B}(\bar {B} \bar{\nu}_\tau) / \mathcal{B}(\bar{B} \ell^- \bar{\nu}_\ell)$, where $\ell^-$ denotes an electron or a muon....
Purpose We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced gastric adenocarcinoma. Patients and Methods conducted international (Australia New Zealand, South Korea, Canada) randomized phase II trial which patients were randomly assigned at a two-to-one ratio stratified by lines prior chemotherapy for disease (one v two) region. Eligible received best supportive care plus regorafenib 160 mg or matching placebo orally on days 1 to 21 each 28-day cycle until...
Nivolumab showed improvement in overall survival (OS) ATTRACTION-2, the first phase 3 study patients with gastric/gastroesophageal junction (G/GEJ) cancer treated ≥ 2 chemotherapy regimens. The 2-year follow-up results of ATTRACTION-2 are presented herein.ATTRACTION-2 was a randomized, double-blind, placebo-controlled, trial (49 sites; Japan, South Korea, and Taiwan). median (min-max) period 27.3 (24.1-36.3) months. primary endpoint OS. A subanalysis OS performed based on best response...
Combined therapy with dabrafenib plus trametinib was approved in several countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an earlier interim analysis 23 response-assessable patients the ATC cohort phase II Rare Oncology Agnostic Research (ROAR) basket study. We report updated describing efficacy and safety full ROAR 36 ∼4 years additional study follow-up.ROAR (NCT02034110) is open-label, nonrandomized, evaluating rare cancers. The comprised unresectable...
We present measurements of the branching fractions for decays $B\to K \mu^{+}\mu^{-}$ and e^{+}e^{-}$, their ratio ($R_{K}$), using a data sample 711 $fb^{-1}$ that contains $772 \times 10^{6}$ $B\bar{B}$ events. The were collected at $\Upsilon(4S)$ resonance with Belle detector KEKB asymmetric-energy $e^{+}e^{-}$ collider. $R_{K}$ is measured in five bins dilepton invariant-mass-squared ($q^{2}$): $q^{2} \in (0.1, 4.0), (4.0, 8.12), (1.0, 6.0)$, $(10.2, 12.8)$ ($>14.18) GeV^{2}/c^{4}$,...
The ret/PTC oncogene, a rearranged form of the vet proto-oncogene, has been found to be restricted human papillary thyroid carcinomas.This report shows that transgenic mice with thyroid-targeted expression retlPTC1 oncogene developed carcinomas considerable similarities carcinomas, particularly in nuclear cytologic features and presence local invasion.Our findings indicate reflPTC1 is not only biomarker associated but also proven specific genetic event leading development carcinoma.
We report the observation of prompt J/psi via double cc; production from e+e- continuum. In this process one pair fragments into a meson while remaining either produces charmonium state or open charm. Both cases have been experimentally observed. find cross sections sigma[e+e- -->J/psieta(c)(gamma)]xB(eta(c)-->>or=4 charged)=(0.033(+0.007)(-0.006)+/-0.009) pb and sigma(e+e- -->J/psiD(*+)X)=(0.53(+0.19)(-0.15)+/-0.14) infer -->J/psicc;)/sigma(e+e- -->J/psiX)=0.59(+0.15)(-0.13)+/-0.12. These...
We observe evidence for D0−¯¯¯D0 mixing by measuring the difference in apparent lifetime when a D0 meson decays to CP eigenstates K+K− and π+π− it final state K−π+. find relative of lifetimes yCP be [1.31±0.32(stat)±0.25(syst)]%, 3.2 standard deviations from zero. also search asymmetry between ¯¯¯D0 decays; no violation is found. These results are based on 540 fb−1 data recorded Belle detector at KEKB e+e− collider.Received 31 March 2007DOI:https://doi.org/10.1103/PhysRevLett.98.211803©2007...
We report the first observation of e+e−→Υ(1S)π+π−, Υ(2S)π+π−, and evidence for e+e−→Υ(3S)π+π−, Υ(1S)K+K−, near peak Υ(5S) resonance at s∼10.87 GeV. The results are based on a data sample 21.7 fb−1 collected with Belle detector KEKB e+e− collider. Attributing signals to resonance, partial widths Γ(Υ(5S)→Υ(1S)π+π−)=0.59±0.04(stat)±0.09(syst) MeV Γ(Υ(5S)→Υ(2S)π+π−)=0.85±0.07(stat)±0.16(syst) obtained from observed cross sections. These values exceed by more than 2 orders magnitude previously...
We present an improved measurement of the branching fraction for electroweak penguin process $B\ensuremath{\rightarrow}{X}_{s}{\ensuremath{\ell}}^{+}{\ensuremath{\ell}}^{\ensuremath{-}}$, where $\ensuremath{\ell}$ is electron or a muon and ${X}_{s}$ hadronic system containing $s$-quark. The based on sample $152\ifmmode\times\else\texttimes\fi{}{10}^{6}$ $\ensuremath{\Upsilon}(4S)\ensuremath{\rightarrow}B\overline{B}$ events collected with Belle detector at KEKB energy asymmetric...
Cisplatin plus 5-fluorouracil has been globally accepted as a standard regimen for the treatment advanced gastric cancer. However, cisplatin several disadvantages, including renal toxicity and need admission. S-1 become cancer in East Asia. This phase III study was designed to evaluate potential benefits of adding docetaxel without platinum compound patients with Patients were randomly assigned receive or alone. The group received on day 1 oral days 1–14 21-day cycle. alone 1–28 42-day...
Background Despite many attempts to establish pre-treatment prognostic markers understand the clinical biology of esophageal adenocarcinoma (EAC), validated biomarkers or parameters remain elusive. We generated and analyzed tumor transcriptome develop a practical biomarker signature in EAC. Methodology/Principal Findings Untreated endoscopic biopsy specimens were obtained from 64 patients undergoing surgery chemoradiation. Using DNA microarray technology, genome-wide gene expression...